2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Checkpoint Inhibitor, Gene Therapy, Immunotherapy, Monoclonal Antibody Therapy, Artificial Intelligence (AI), Deep Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Elderly, Animal Model
PAPER

2180 Belantamab retains B-cell maturation antigen (BCMA)-binding ability in the presence of BCMA escape mutations

Hanny Musa, Francesco Maura, MD2, Marc-Steffen Steffen Raab, MD3, Chanhyung Bae4, Mary Birchler5, Chun-Wa Chung6, Boyenoh Gaye7, Panchali Goswami8, Zeyad Khalaf, PharmD9, Kelly McGrath10, Jorge Mouro11, James Parker, PhD12, Huaping Tang13, Rakesh Popat, MD14, Adam D. Cohen, MD15, Daniel E. Lowther16
1 GSK, Baar Onyx, Switzerland
2 Memorial Sloan Kettering Cancer Center, New York, NY, United States
3 Heidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital and Medical Faculty, Heidelberg, Germany
4 GSK, Upper Providence, PA, United States
5 GSK, Upper Providence, PA, United States
6 GSK, Stevenage, United Kingdom
7 GSK, Upper Providence, PA, United States
8 GSK, Stevenage, United Kingdom
9 GSK, London, United Kingdom
10 GSK, Upper Providence, PA, United States
11 GSK, Baar Onyx, Switzerland
12 GSK, London, United Kingdom
13 GSK, Upper Providence, PA, United States
14 National Institute for Health Research University College London Hospitals Clinical Research Facility, University College London Hospitals National Health Service Foundation Trust, London, United Kingdom
15 Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States
16 GSK, Stevenage, United Kingdom

Introduction: Targeting BCMA has led to unprecedented overall survival outcomes for patients with multiple myeloma (MM). BCMA-targeting therapies include the antibody-drug conjugate belantamab mafodotin (belamaf; comprising the monoclonal antibody belantamab coupled to a cytotoxic payload), chimeric antigen receptor T-cell (CAR-T) therapies, and bispecific antibodies (BsAbs). Mutations in BCMA have been reported following treatment with BCMA-targeting CAR-T and BsAb therapies (Lee et al. Nat Med 2023;29:2295–306), and these mutations can affect the efficacy of subsequent therapies that also target BCMA. We sought to identify shared epitopes between BsAbs and belamaf and delineate interactions between antibody paratopes and the antigens’ epitope to understand the impacts for optimized anti-BCMA treatment sequencing.

Methods: To map BCMA epitopes, we determined structures of soluble BCMA (sBCMA) bound to BCMA-directed therapies (belantamab [monoclonal antibody only], teclistamab, alnuctamab) using either cryo-electron microscopy or X-ray crystallography. We also performed protein-protein binding measurements between recombinant sBCMA variants (wild-type and antigen-escape mutants including R27P, S30Del, P33S, and P34Del) and BCMA-directed therapies, including belantamab, BsAbs (teclistamab, elranatamab, and linvoseltamab), and antigen-binding domain of CAR-Ts (ciltacabtagene autoleucel and idecabtagene vicleucel).

Results: Structural epitope-mapping analyses revealed that belantamab, teclistamab, and alnuctamab exhibit distinct binding orientations, indicating divergent modes of BCMA conformational recognition, with 12 shared common binding residues. Importantly, belantamab engaged its target with a larger epitope footprint (22 residues) extending further N- and C- terminally compared to teclistamab (18 residues) and alnuctamab (16 residues). Additionally, the near-atomic resolution structure of belantamab-sBCMA complex, solved at 2.65 Å resolution, enabled visualization of the antigen-escape BCMA residues in the context of the complex formation. The epitope-mapping analysis supported the protein-protein binding measurements between sBCMA and BsAbs, showing that belantamab binding was preserved against all 4 antigen-escape BCMA mutants reported to emerge following anti-BCMA CAR-T or BsAb therapies (R27P, S30Del, P33S, and P34Del; Lee et al. Nat Med 2023). In contrast to this preserved binding with belantamab, BsAbs showed variable loss of binding, consistent with the previously published cell-based assay data (Lee et al. Nat Med 2023). We also found that these known escape mutations did not impair the binding of CAR-T therapy-derived antigen-binding domains, for which data have not been published previously to our knowledge.

Conclusions: While belantamab shared binding epitopes on BCMA with BsAbs, belantamab’s expanded binding footprint and distinct binding orientation offer a unique and robust interaction profile, potentially influencing its therapeutic efficacy. Binding of belantamab, likely as a result of its interaction profile, and binding of the CAR-T-derived antigen binding domains, were not impacted by antigen escape BCMA mutations known to occur with other anti-BCMA therapies. These findings underscore the divergent modes of BCMA engagement employed by each anti-BCMA modality, resulting in unique binding geometries and receptor interactions. This divergence can offer strategic opportunities when considering optimal sequencing of BCMA-targeting therapies.

Daniel E. Lowther: GSK - Current equity holder in publicly-traded company; GSK - Current Employment